Worldwide MR Vaccines Industry to 2028 – Featuring PT Bio Farma, Bio-Manguinhos and BE Vaccines Among Others – ResearchAndMarkets.com

Worldwide MR Vaccines Industry to 2028 – Featuring PT Bio Farma, Bio-Manguinhos and BE Vaccines Among Others – ResearchAndMarkets.com




Worldwide MR Vaccines Industry to 2028 – Featuring PT Bio Farma, Bio-Manguinhos and BE Vaccines Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “MR Vaccines Market, by Vaccine Brand, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028” report has been added to ResearchAndMarkets.com’s offering.

Measles and rubella is a live virus vaccine that protects against infection with the measles and rubella viruses. It works by causing the body to produce its antiviral defenses (antibodies). Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and 10-day measles) is a highly contagious infectious disease.

Measles infection can result in significant complications such as pneumonia, ear infections, sinus infections, convulsions (seizures), brain damage, and death. Adults and children under the age of 5 years are at a higher risk of serious complications and mortality. When pregnant women contract rubella (also known as German measles), it can result in miscarriages, stillbirths, or birth abnormalities in their unborn children.

Measles and Rubella (MR) vaccine is a subcutaneous injection for active immunization against Measles and Rubella in young adults, adolescents, children, and infants at risk. Increasing incidence of Measles and Rubella (MR), ongoing clinical trials to develop MR vaccines, growing awareness about immunization services, rising government initiatives to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are the major factors that are expected to drive growth of the MR vaccines market over the forecast period.

Key features of the study:

  • This report provides an in-depth analysis of the MR vaccines market, and provides market size (US$ Mn. and No. of Doses in Mn.), and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the MR vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The MR vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the MR vaccines market

Detailed Segmentation:

MR Vaccines Market, By Vaccine Brand:

  • MR Vaccine
  • MRBEV (BE LTD.)

MR Vaccines Market, By Distribution Channel:

  • Public
  • Private

MR Vaccines Market, By Region:

  • Commonwealth of Independent States (CIS) Countries
  • Russia
  • Uzbekistan
  • Kazakhstan
  • Ukraine
  • Turkmenistan
  • Belarus
  • Armenia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Honduras
  • Colombia
  • Peru
  • Chile
  • Europe
  • Turkey
  • Asia Pacific
  • Pakistan
  • Indonesia
  • Bangladesh
  • Philippines
  • Vietnam
  • Thailand
  • Myanmar
  • Malaysia
  • Cambodia
  • Nepal
  • Sri Lanka
  • Papua New Guinea
  • Mauritius
  • Middle East
  • UAE
  • Israel
  • Iraq
  • Iran
  • Saudi Arabia
  • Jordan
  • Qatar
  • Oman
  • Syrian Arab Republic
  • Africa
  • Nigeria
  • Tanzania
  • Democratic Republic of Congo
  • Ethiopia
  • Kenya
  • South Africa
  • Egypt
  • Morocco
  • Ghana
  • Uganda
  • Burkina Faso
  • Angola
  • Algeria
  • Zimbabwe
  • Tunisia
  • Botswana
  • Libya
  • Namibia

Company Profiles

  • PT Bio Farma
  • Bio-Manguinhos
  • BE Vaccines
  • Serum Institute of India
  • Crucell Switzerland AG

For more information about this report visit https://www.researchandmarkets.com/r/wlijqf

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900